Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 4.8
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of PYPD is 12 and suggests 141% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Data is available to registered users only
Buy
Sell